Can tirzepatide (Mounjaro) cause diarrhea?

Can Mounjaro Cause Diarrhea?

Yes, Mounjaro (tirzepatide) commonly causes diarrhea as a gastrointestinal side effect, occurring in 12-23% of patients, making it one of the most frequent adverse events associated with this medication. 1, 2

Incidence and Characteristics

Diarrhea is among the most common gastrointestinal adverse events with tirzepatide:

• Diarrhea occurs in 12-22% of patients across clinical trials, with rates varying by dose 1
• The incidence is dose-dependent, increasing with higher doses (5 mg, 10 mg, and 15 mg weekly) 3, 4
• Tirzepatide demonstrates significantly higher diarrhea rates compared to placebo (OR 2.07; 95% CI 1.60-2.68) 4
• When compared to other GLP-1 receptor agonists, tirzepatide shows the highest risk of inducing diarrhea 5
• The adverse event is typically transient and of mild-to-moderate severity 6

Clinical Context and Mechanism

The gastrointestinal side effects result from tirzepatide's mechanism of action:

• As a dual GIP/GLP-1 receptor agonist, tirzepatide delays gastric emptying, which contributes to GI symptoms 2
• Diarrhea appears alongside other common GI effects including nausea (12-24%), vomiting (2-13%), and constipation 1, 3
• The FDA label explicitly lists diarrhea as a common gastrointestinal adverse reaction 2

Important Safety Considerations

Monitor for complications related to diarrhea:

• Dehydration risk: Diarrhea, along with nausea and vomiting, can lead to dehydration, which if severe may cause acute kidney injury 2
• Renal monitoring: Monitor renal function when initiating or escalating doses in patients with renal impairment who report severe gastrointestinal adverse reactions 2
• Severe cases: In placebo-controlled trials, severe gastrointestinal adverse reactions occurred in 0.4-1.3% of tirzepatide-treated patients versus 0.9% with placebo 2

Weight Loss Independence

Importantly, the weight loss efficacy of tirzepatide is independent of diarrhea occurrence:

• Mean weight reduction was consistent between participants who reported diarrhea and those who did not 6
• Mediation analyses showed minimal contribution (<6%) of GI adverse events to overall weight change differences 6
• This suggests the therapeutic benefit is not simply due to GI side effects 6

Clinical Management Approach

When diarrhea occurs with tirzepatide:

• Ensure adequate hydration and monitor for signs of dehydration (dizziness on standing, decreased urine output) 2
• Most cases are self-limited and resolve with continued therapy 6, 3
• Consider dose adjustment if symptoms are severe or persistent 2
• Discontinue if severe gastrointestinal disease develops 2